The Albany Times Union has reported that Vireo Health of New York, formerly Empire State Health Solutions, will use the Captisol technology that it has licensed from Ligand Pharmaceuticals to pursue a pharmaceutical grade medical cannabis solution to a large and poorly treated medical condition:
The initial focus will be to develop cannabinoid medications for treatment of chronic pain, at a time when abuse of opioid painkillers is soaring, according to Vireo Chief Medical Officer Laura Bultman.
Vireo Health announced the licensing of Ligand’s technology on Wednesday.
Read Claire Hughes’ “Parent of N.Y. medical marijuana company seeks to make FDA-approved drugs”: http://blog.timesunion.com/healthcare/parent-of-n-y-medical-marijuana-company-seeks-to-make-fda-approved-drugs/4027/
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.